Unknown

Dataset Information

0

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain.

ABSTRACT:

SUBMITTER: Pacheco JM 

PROVIDER: S-EPMC6685853 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
| S-EPMC8645705 | biostudies-literature
Unknown First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
| S-EPMC7734005 | biostudies-literature
Unknown Nine unanswered questions about cytokinesis.
| S-EPMC5626534 | biostudies-literature
Unknown Unanswered Questions in Contemporary Heart Failure.
| S-EPMC5843471 | biostudies-other
Unknown Emerging therapies for hemophilia: controversies and unanswered questions.
| S-EPMC5931262 | biostudies-literature
Unknown Unanswered Questions Regarding Sex and BMP/TGF-? Signaling.
| S-EPMC6027345 | biostudies-literature
Unknown Respiratory Viral Infections in Athletes: Many Unanswered Questions.
| S-EPMC8965548 | biostudies-literature
Unknown Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.
| S-EPMC6774054 | biostudies-literature
Unknown Questions left unanswered: how the brain responds to missing information.
| S-EPMC3788781 | biostudies-literature
Unknown Remote ischaemic conditioning for stroke: unanswered questions and future directions.
| S-EPMC8258051 | biostudies-literature